Targeting mammalian target of rapamycin (mTOR) for health and diseases

Chi Kwan Tsang, Haiyan Qi, Leroy F. Liu, X. F.Steven Zheng

Research output: Contribution to journalReview articlepeer-review

369 Citations (Scopus)


The macrolide rapamycin is used clinically to treat graft rejection and restenosis. Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. New studies have linked mTOR to several human diseases including cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. Recent data have also revealed that mTOR is involved in the regulation of lifespan and in age-related diseases. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway.

Original languageEnglish
Pages (from-to)112-124
Number of pages13
JournalDrug Discovery Today
Issue number3-4
Publication statusPublished - Feb 2007
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Targeting mammalian target of rapamycin (mTOR) for health and diseases'. Together they form a unique fingerprint.

Cite this